Canada Markets close in 3 hrs 26 mins

PharmaTher Holdings Ltd. (PHRM.CN)

Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
Add to watchlist
0.8900+0.0900 (+11.25%)
As of 12:05PM EDT. Market open.
Full screen
Previous Close0.8000
Open0.8000
Bid0.8800 x N/A
Ask0.9000 x N/A
Day's Range0.7500 - 0.9200
52 Week Range0.1900 - 0.9600
Volume898,786
Avg. Volume674,044
Market Cap60.585M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • PharmaTher To Present At The H.C. Wainwright Psychedelics In Psychiatry And Beyond Virtual Conference
    GlobeNewswire

    PharmaTher To Present At The H.C. Wainwright Psychedelics In Psychiatry And Beyond Virtual Conference

    TORONTO, June 16, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, today announced that Fabio Chianelli, Chief Executive Officer, will be presenting at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference on June 17, 2021. The corporate presentation will be available on-demand starting at 7:00 am ET. For more information about this event and to attend, visit: https:

  • PharmaTher Files FDA Pre-IND Meeting Request and Briefing Package For KETABET™ To Treat Depression
    GlobeNewswire

    PharmaTher Files FDA Pre-IND Meeting Request and Briefing Package For KETABET™ To Treat Depression

    Potential for FDA 505(b)(2) regulatory pathway approval and FDA Fast Track designationAdvancing Ketamine and KETABET™ alone or in a microneedle patch for intradermal administrationPotential next generation treatment for mental health, neurological and pain disorders TORONTO, June 15, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to announce that it has filed a pre-Investigati

  • PharmaTher Provides Research and Development Update and Milestones for 2021
    GlobeNewswire

    PharmaTher Provides Research and Development Update and Milestones for 2021

    TORONTO, June 10, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to provide an update on the research and development initiatives of its psychedelic product programs and upcoming milestones for 2021. “We are well-positioned, both financially and operationally, to execute on our remaining milestones for 2021, which includes completing a Phase 2 study with ketamine to treat Park